Hormonal
Treatment with GLP-1 receptor agonists (semaglutide or dulaglutide) significantly reduces biochemical markers of liver fibrosis (FIB-4 score) and inflammation (De Ritis ratio) in patients with type 2 diabetes and MASLD over 180 days.
For patients with Type 2 Diabetes and fatty liver disease, GLP-1 agonists like semaglutide or dulaglutide (taken weekly) can significantly improve liver health markers (specifically fibrosis risk scores) over 6 months, even without changes to diet or exercise. This suggests these drugs offer liver-specific benefits beyond just weight loss or blood sugar control.
we obtained a statistically significant decrease in FIB-4 (p < 0.001)... we obtained a decrease in the De Ritis ratio from 1 to 0.84 that turned out to be statistically significant (p < 0.05).
Why this rating
Small sample size (n=41), short duration (180 days), lack of control group, and mixed drug types (semaglutide/dulaglutide) limit generalizability.
Source
Does Therapy with Glucagon-like Peptide 1 Receptor Agonists Have an Effect on Biochemical Markers of Metabolic-Dysfunction-Associated Steatotic Liver Disease (MASLD)? Pleiotropic Metabolic Effect of Novel Antidiabetic Drugs in Patients with Diabetes—Interventional Study
Marcin Hachuła et al. · Pharmaceuticals · 2023
DOI 10.3390/ph16091190
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →